165 related articles for article (PubMed ID: 2221645)
21. Long-term treatment with calcitriol in postmenopausal osteoporosis.
Caniggia A; Nuti R; Lore F; Martini G; Turchetti V; Righi G
Metabolism; 1990 Apr; 39(4 Suppl 1):43-9. PubMed ID: 2325571
[TBL] [Abstract][Full Text] [Related]
22. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY
N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454
[TBL] [Abstract][Full Text] [Related]
23. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
[TBL] [Abstract][Full Text] [Related]
24. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial.
Meunier PJ; Slosman DO; Delmas PD; Sebert JL; Brandi ML; Albanese C; Lorenc R; Pors-Nielsen S; De Vernejoul MC; Roces A; Reginster JY
J Clin Endocrinol Metab; 2002 May; 87(5):2060-6. PubMed ID: 11994341
[TBL] [Abstract][Full Text] [Related]
25. Calcitriol in the treatment of postmenopausal osteoporosis.
Aloia JF; Vaswani A; Yeh JK; Ellis K; Yasumura S; Cohn SH
Am J Med; 1988 Mar; 84(3 Pt 1):401-8. PubMed ID: 3279769
[TBL] [Abstract][Full Text] [Related]
26. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
27. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
Lindsay R; Nieves J; Formica C; Henneman E; Woelfert L; Shen V; Dempster D; Cosman F
Lancet; 1997 Aug; 350(9077):550-5. PubMed ID: 9284777
[TBL] [Abstract][Full Text] [Related]
28. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
[TBL] [Abstract][Full Text] [Related]
29. Calcium absorption in postmenopausal osteoporosis: benefit of HRT plus calcitriol, but not HRT alone, in both malabsorbers and normal absorbers.
Holzherr ML; Retallack RW; Gutteridge DH; Price RI; Faulkner DL; Wilson SG; Will RK; Stewart GO; Stuckey BG; Prince RL; Criddle RA; Kent GN; Bhagat CI; Dhaliwal SS; Jamrozik K
Osteoporos Int; 2000; 11(1):43-51. PubMed ID: 10663358
[TBL] [Abstract][Full Text] [Related]
30. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial.
Prestwood KM; Kenny AM; Kleppinger A; Kulldorff M
JAMA; 2003 Aug; 290(8):1042-8. PubMed ID: 12941676
[TBL] [Abstract][Full Text] [Related]
31. Correlations of Serum Hormones and Bone Mineral Density with Fracture and Balance Ability of Postmenopausal Patients and Effects of Calcitriol.
Xu L; Liu B; Li P; Li J; Wang J; Han J; Yang N
Med Sci Monit; 2018 Oct; 24():7309-7315. PubMed ID: 30315646
[TBL] [Abstract][Full Text] [Related]
32. Calcitriol and alendronate combination treatment in menopausal women with low bone mass.
Malavolta N; Zanardi M; Veronesi M; Ripamonti C; Gnudi S
Int J Tissue React; 1999; 21(2):51-9. PubMed ID: 10568224
[TBL] [Abstract][Full Text] [Related]
33. Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol.
Stempfle HU; Werner C; Echtler S; Wehr U; Rambeck WA; Siebert U; Uberfuhr P; Angermann CE; Theisen K; Gärtner R
Transplantation; 1999 Aug; 68(4):523-30. PubMed ID: 10480411
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate.
Richy F; Ethgen O; Bruyere O; Reginster JY
Osteoporos Int; 2004 Apr; 15(4):301-10. PubMed ID: 14740153
[TBL] [Abstract][Full Text] [Related]
35. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
[TBL] [Abstract][Full Text] [Related]
36. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
37. A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D.
Henriksen K; Byrjalsen I; Andersen JR; Bihlet AR; Russo LA; Alexandersen P; Valter I; Qvist P; Lau E; Riis BJ; Christiansen C; Karsdal MA;
Bone; 2016 Oct; 91():122-9. PubMed ID: 27462009
[TBL] [Abstract][Full Text] [Related]
38. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment.
Miller PD; Schwartz EN; Chen P; Misurski DA; Krege JH
Osteoporos Int; 2007 Jan; 18(1):59-68. PubMed ID: 17013567
[TBL] [Abstract][Full Text] [Related]
39. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
[TBL] [Abstract][Full Text] [Related]
40. Combined treatment with calcitonin and 1,25-dihydroxyvitamin D3 for osteoporosis in women.
Eriksson SA; Lindgren JU
Calcif Tissue Int; 1993 Jul; 53(1):26-8. PubMed ID: 8348381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
